219 related articles for article (PubMed ID: 33079366)
1. Treatment of Necrotizing Soft Tissue Infections: IVIG.
Madsen MB; Bergsten H; Norrby-Teglund A
Adv Exp Med Biol; 2020; 1294():105-125. PubMed ID: 33079366
[TBL] [Abstract][Full Text] [Related]
2. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
Sriskandan S; Ferguson M; Elliot V; Faulkner L; Cohen J
J Antimicrob Chemother; 2006 Jul; 58(1):117-24. PubMed ID: 16670109
[TBL] [Abstract][Full Text] [Related]
3. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach.
Norrby-Teglund A; Muller MP; Mcgeer A; Gan BS; Guru V; Bohnen J; Thulin P; Low DE
Scand J Infect Dis; 2005; 37(3):166-72. PubMed ID: 15849047
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for severe infections: a survey of Canadian specialists.
Laupland KB; Boucher P; Rotstein C; Cook DJ; Doig CJ
J Crit Care; 2004 Jun; 19(2):75-81. PubMed ID: 15236139
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between Immunoglobulin Dose Administered and Plasma Neutralization of Streptococcal Superantigens in Patients With Necrotizing Soft Tissue Infections.
Bergsten H; Madsen MB; Bergey F; Hyldegaard O; Skrede S; Arnell P; Oppegaard O; Itzek A; Perner A; Svensson M; Norrby-Teglund A;
Clin Infect Dis; 2020 Oct; 71(7):1772-1775. PubMed ID: 31916575
[TBL] [Abstract][Full Text] [Related]
6. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model.
Tarnutzer A; Andreoni F; Keller N; Zürcher C; Norrby-Teglund A; Schüpbach RA; Zinkernagel AS
Clin Microbiol Infect; 2019 Apr; 25(4):512.e7-512.e13. PubMed ID: 30025835
[TBL] [Abstract][Full Text] [Related]
7. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T; Wilson C; Curtis N; Norrby-Teglund A; Sriskandan S
Clin Infect Dis; 2018 Oct; 67(9):1434-1436. PubMed ID: 29788397
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.
Linnér A; Darenberg J; Sjölin J; Henriques-Normark B; Norrby-Teglund A
Clin Infect Dis; 2014 Sep; 59(6):851-7. PubMed ID: 24928291
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review.
Cawley MJ; Briggs M; Haith LR; Reilly KJ; Guilday RE; Braxton GR; Patton ML
Pharmacotherapy; 1999 Sep; 19(9):1094-8. PubMed ID: 10610017
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections.
Norrby-Teglund A; Ihendyane N; Darenberg J
Scand J Infect Dis; 2003; 35(9):683-9. PubMed ID: 14620155
[TBL] [Abstract][Full Text] [Related]
11. A survey of physician's attitudes regarding management of severe group A streptococcal infections.
Valiquette L; Low DE; Chow R; McGeer AJ
Scand J Infect Dis; 2006; 38(11-12):977-82. PubMed ID: 17148064
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin for adjunctive treatment of severe infections in ICUs.
Aubron C; Berteau F; Sparrow RL
Curr Opin Crit Care; 2019 Oct; 25(5):417-422. PubMed ID: 31335381
[TBL] [Abstract][Full Text] [Related]
13. Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom.
Baxter M; Morgan M
Emerg Infect Dis; 2017 Jan; 23(1):127-129. PubMed ID: 27983491
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial.
Madsen MB; Hjortrup PB; Hansen MB; Lange T; Norrby-Teglund A; Hyldegaard O; Perner A
Intensive Care Med; 2017 Nov; 43(11):1585-1593. PubMed ID: 28421246
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.
Kaul R; McGeer A; Norrby-Teglund A; Kotb M; Schwartz B; O'Rourke K; Talbot J; Low DE
Clin Infect Dis; 1999 Apr; 28(4):800-7. PubMed ID: 10825042
[TBL] [Abstract][Full Text] [Related]
16. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
Norrby-Teglund A; Kaul R; Low DE; McGeer A; Newton DW; Andersson J; Andersson U; Kotb M
J Immunol; 1996 Apr; 156(8):3057-64. PubMed ID: 8609429
[TBL] [Abstract][Full Text] [Related]
17. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
[TBL] [Abstract][Full Text] [Related]
18. Beta-Hemolytic Streptococci and Necrotizing Soft Tissue Infections.
Bruun T; Rath E; Oppegaard O; Skrede S
Adv Exp Med Biol; 2020; 1294():73-86. PubMed ID: 33079364
[TBL] [Abstract][Full Text] [Related]
19. [The role of IVIG in treatment of generalized infections].
Lewandowicz-Uszyńska A
Postepy Hig Med Dosw; 2002; 56 Suppl():85-90. PubMed ID: 12661418
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.
Carapetis JR; Jacoby P; Carville K; Ang SJ; Curtis N; Andrews R
Clin Infect Dis; 2014 Aug; 59(3):358-65. PubMed ID: 24785239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
